Epidemiology of pediatric sarcoma in Iran.
Iran national cancer registry
epidemiology
malignant bone tumor
osteosarcoma
pediatric sarcoma
rhabdomyosarcoma
soft tissue sarcoma
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
16
04
2022
received:
18
11
2021
accepted:
31
05
2022
pubmed:
28
6
2022
medline:
27
1
2023
entrez:
27
6
2022
Statut:
ppublish
Résumé
Pediatric sarcomas are divided into two major groups of soft-tissue sarcomas (STSs) and malignant bone tumors (MBTs). The aim of the present study was to determine the incidence and survival rate of STSs and MBTs in the Iranian population based on diagnosis date, gender, age, and histological types. Data was retrieved from Iran National Cancer Registry between 2008 and 2015. The dataset was classified according to the third edition of the International Classification of Childhood Cancer. The survival information was merely available for 291 (21% of total data), including 142 (49%) MBTs and 149 (51%) STSs. The age-standardized incidence rates (ASIRs) and five-year survival rates were calculated. The present study is the first comprehensive study of pediatric sarcomas in Iran, in which a lower incidence and survival rate of MBTs and STSs compared with high-income countries were found. However, the survival rates of these malignancies were higher in high-income countries compared to Iran. This study showed the need to improve the quantity and quality of the population-based registry in Iran for acquiring progress in the prevention and control of sarcomas.
Sections du résumé
BACKGROUND
Pediatric sarcomas are divided into two major groups of soft-tissue sarcomas (STSs) and malignant bone tumors (MBTs).
AIMS
The aim of the present study was to determine the incidence and survival rate of STSs and MBTs in the Iranian population based on diagnosis date, gender, age, and histological types.
METHODS AND RESULTS
Data was retrieved from Iran National Cancer Registry between 2008 and 2015. The dataset was classified according to the third edition of the International Classification of Childhood Cancer. The survival information was merely available for 291 (21% of total data), including 142 (49%) MBTs and 149 (51%) STSs. The age-standardized incidence rates (ASIRs) and five-year survival rates were calculated.
CONCLUSION
The present study is the first comprehensive study of pediatric sarcomas in Iran, in which a lower incidence and survival rate of MBTs and STSs compared with high-income countries were found. However, the survival rates of these malignancies were higher in high-income countries compared to Iran. This study showed the need to improve the quantity and quality of the population-based registry in Iran for acquiring progress in the prevention and control of sarcomas.
Identifiants
pubmed: 35761437
doi: 10.1002/cnr2.1660
pmc: PMC9875610
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1660Informations de copyright
© 2022 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Asian Pac J Cancer Prev. 2013;14(5):3237-41
pubmed: 23803110
Ann R Coll Surg Engl. 2015 Sep;97(6):425-33
pubmed: 26274756
J Glob Oncol. 2019 Mar;5:1-6
pubmed: 30917068
Cancer Rep (Hoboken). 2023 Jan;6(1):e1660
pubmed: 35761437
MMWR Morb Mortal Wkly Rep. 2018 Jun 29;67(25):707-713
pubmed: 29953430
BMC Cancer. 2010 Jul 06;10:357
pubmed: 20604931
Cancer Lett. 2016 Mar 1;372(1):110-7
pubmed: 26742461
Eur J Cancer. 2006 Sep;42(13):2136-49
pubmed: 16919777
Nat Rev Dis Primers. 2019 Jan 7;5(1):1
pubmed: 30617281
Clin Sarcoma Res. 2012 Oct 04;2(1):14
pubmed: 23036164
J Pediatr Hematol Oncol. 2010 Jul;32(5):376-82
pubmed: 20588194
BMC Cancer. 2020 Jan 10;20(1):30
pubmed: 31924184
Lancet Oncol. 2017 Jun;18(6):719-731
pubmed: 28410997
Ann Oncol. 2010 May;21 Suppl 5:v204-13
pubmed: 20555083
BMC Health Serv Res. 2013 May 06;13:169
pubmed: 23647828
Eur J Cancer. 2006 Sep;42(13):1915-51
pubmed: 16919762
J Clin Oncol. 2009 Jul 10;27(20):3391-7
pubmed: 19398574
Chin J Cancer Res. 2014 Jun;26(3):285-92
pubmed: 25035655
Cancer. 2005 Apr 1;103(7):1457-67
pubmed: 15712273
Cancer. 2009 Sep 15;115(18):4218-26
pubmed: 19536876
Front Oncol. 2020 Jan 14;9:1428
pubmed: 31993366
Br J Cancer. 2009 Jan 13;100(1):188-93
pubmed: 19127271
BMJ. 2004 May 1;328(7447):1073
pubmed: 15117797
Cancer Sci. 2018 Feb;109(2):422-434
pubmed: 29178401
PLoS One. 2017 Jul 24;12(7):e0181805
pubmed: 28742150
Cancer. 2009 Jun 15;115(12):2744-54
pubmed: 19396819
Acta Oncol. 2016 Sep - Oct;55(9-10):1145-1151
pubmed: 27549334
Eur J Cancer. 2006 Sep;42(13):2124-35
pubmed: 16919776
BMC Musculoskelet Disord. 2018 Aug 18;19(1):297
pubmed: 30121085
Eur J Cancer. 2009 Sep;45(13):2367-75
pubmed: 19349163
Lancet Oncol. 2014 Jan;15(1):35-47
pubmed: 24314616